文献速递湿疹皮炎与荨麻疹

曲罗芦单抗治疗成人中重度特应性皮炎的2年长期安全性与疗效:ECZTEND开放标签扩展试验的中期分析

Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
PubMed 文献 · J Am Acad Dermatol · 2022-07-19

ECZTEND是一项正在进行的5年开放标签扩展试验,纳入既往曲罗芦单抗母试验的中重度特应性皮炎成人患者,评估曲罗芦单抗联合可选外用糖皮质激素的安全性与疗效。事后中期分析显示,安全性分析集(N=1174)暴露校正不良事件率为237.8例/100患者年,常见不良事件发生率与母试验相当但更低;接受2年曲罗芦单抗治疗者中82.5%达到EASI-75(N=345),疗效维持。

要点

  • 安全性分析集N=1174,暴露校正不良事件率为237.8例/100患者年。
  • 常见不良事件发生率与母试验相当,但发生率更低。
  • 接受2年曲罗芦单抗治疗者中82.5%达到EASI-75(N=345)。

核心结论

  • 曲罗芦单抗治疗2年耐受性良好,并维持对特应性皮炎体征和症状的长期控制。

研究设计与样本

  • 正在进行的5年开放标签扩展试验ECZTEND(NCT03587805),纳入既往曲罗芦单抗母试验的中重度特应性皮炎成人患者,给予曲罗芦单抗联合可选外用糖皮质激素。
  • 本次为事后中期分析,安全性分析纳入完成母试验并入组ECZTEND的成人,不论曲罗芦单抗暴露时长;疗效分析纳入在ECZTEND接受曲罗芦单抗治疗≥1年的成人,并对治疗2年者(母试验1年、ECZTEND 1年)进行亚组分析。

主要发现

  • 安全性分析集N=1174,暴露校正不良事件率为237.8例/100患者年。
  • 常见不良事件的暴露校正发生率与母试验相当,但发生率更低。
  • 接受2年曲罗芦单抗治疗者中82.5%达到EASI-75(N=345),特应性皮炎范围和严重度的改善得以维持。

关键数值与推荐

  • 主要终点为不良事件数量,另设疗效终点。
  • 接受2年曲罗芦单抗治疗者EASI-75为82.5%(N=345)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 可能存在选择偏倚。
  • 无安慰剂组。
  • 部分参与者在母试验与ECZTEND之间存在治疗间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Additional long-term treatments are needed for moderate-to-severe atopic dermatitis (AD). An ongoing, open-label, 5-year extension trial, ECZTEND (NCT03587805), assesses tralokinumab plus optional topical corticosteroids in participants from previous tralokinumab parent trials (PTs) with moderate-to-severe AD. OBJECTIVE: To evaluate the safety and efficacy of up to 2 years tralokinumab treatment in a post hoc interim analysis. METHODS: Safety analyses included adults from completed PTs enrolled in ECZTEND, regardless of tralokinumab exposure duration. Efficacy analyses included adult participants treated with tralokinumab in ECZTEND for ≥1 year and subgroup analyses of those on tralokinumab for 2 years (1 year from PT, 1 year in ECZTEND). Primary end point was the number of adverse events with additional efficacy end points. RESULTS: Participants on tralokinumab had an exposure-adjusted rate of 237.8 adverse events/100 patient-years' exposure (N = 1174) in the safety analysis set. Exposure-adjusted incidence rates of common adverse events were comparable to PTs, although at lower rates. With 2 years of tralokinumab, improvements in extent and severity of AD were sustained, with Eczema Area and Severity Index (EASI-75) in 82.5% of participants (N = 345). LIMITATIONS: Possible selection bias; no placebo arm; some participants experienced treatment gaps between PTs and ECZTEND. CONCLUSION: Over 2 years, tralokinumab was well tolerated and maintained long-term control of AD signs and symptoms.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022. PMID: 35863467. doi:10.1016/j.jaad.2022.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。